Trump to Ease U.S. Fuel-Economy Standards 
Asian Stocks Fall as Surging Bond Yields Rattle Markets 
Trump, Xi Focus on Trade and AI at White House Summit 
Oil Prices Jump 3% as Houthi Attack Revives Supply Fears 
Germany’s 2026 Growth Outlook Strengthens on Fiscal Spending 
Gold Prices Fall as Treasury Yields Rise on Fed Rate Hike Bets 
ECB May Stop Rate Hikes After December, Capital Economics Says 
U.S. Treasury Yields Surge as 30-Year Hits 22-Year High 
Wall Street Ends Flat as Oil, Treasury Yields and Fed Jitters Rattle Markets 
European Stocks Fall as Bond Yields and Geopolitical Risks Weigh 
US Stock Futures Fall as Treasury Yields Surge Ahead of Trump-Xi Summit 
Fed’s Hammack Says Bond Yield Surge Is Not Driven by Inflation Fears 
China Agrees to Buy 20 Million Tons of U.S. Coal 
US Comfortable With Canada Trade Standoff as Import Bans Loom 
Oil Prices Fall on U.S.-Iran Hormuz Deal Hopes 
Gold Holds Near $4,275 as Rising Treasury Yields Fuel Fed Rate Hike Bets 
Asian Stocks Fall as Bond Yields Surge Ahead of Trump-Xi Summit 
Add as a preferred source on Google
Sanofi's Exclusive Negotiations with Clayton Dubilier & Rice
Sanofi (NASDAQ: SNY) announced on Monday that it has entered exclusive negotiations to sell a 50% controlling stake in its consumer health division, Opella, to the U.S. private equity firm Clayton Dubilier & Rice (CD&R). This strategic move reflects Sanofi's ongoing efforts to optimize its portfolio and focus on core operations.
Valuation and Investment Details
The Opella business is valued at approximately €16 billion ($17.38 billion), equating to 14 times its expected EBITDA for 2024. Additionally, the French public investment bank, Bpifrance, is anticipated to acquire a stake of around 2%, further solidifying the financial backing of this transaction.
Transaction Timeline and Approvals
The proposed sale is subject to definitive agreements and customary statutory approvals. If all goes according to plan, the transaction is expected to close by the second quarter of 2025 at the earliest, marking a significant milestone for both Sanofi and CD&R.
As the negotiations progress, stakeholders will be closely monitoring the developments surrounding this transaction, given its potential impact on Sanofi's market position and future growth strategies.
